Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

NCT00673842 · View on ClinicalTrials.gov ↗

Study Summary

This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.

Interventions

  • OTHER Usual care
  • DEVICE Implantable Cardioverter Defibrillator + Usual Care

Study Locations (20)

Ohio

  • Northeast Ohio Cardiovascular Specialists — Akron
  • The Lindner Research Center — Cincinnati
  • Bethesda North Hospital — Cincinnati
  • Cleveland Clinic — Cleveland
  • The Ohio State University — Columbus

Michigan

  • Washington University Medical School — Saint Louis
  • St. John Providence Hospital — Southfield

New Jersey

  • The Valley Hospital — Ridgewood
  • Associated Cardiovascular Consultants/Lourdes Cardiology Services — Voorhees Township

New York

  • North Shore LIJ — New York
  • New York Presbyterian Hospital — New York

Alabama

  • Heart Center Research LLC — Huntsville

Colorado

  • Colorado Heart and Vascular — Lakewood

Florida

  • James A Haley Veterans' Center — Tampa

Indiana

  • The Heart Group/Deaconess — Evansville

Trial Details

FieldValue
Enrollment Target 700 participants
Start Date 2011-04-18
Est. Completion 2024-10-31
Phase Phase 3

Sponsor

University of Calgary

64 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00673842

The ClinicalTrials.gov registry entry for NCT00673842 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Calgary, which has 64 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Myocardial Infarction appearing as the primary indexed condition, and to 2 interventions — of which Usual care is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00673842 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Ohio, Michigan, New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00673842 about?

NCT00673842 is a clinical study titled "Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction". This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.

What is the current status of trial NCT00673842?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2011-04-18. Estimated completion is 2024-10-31.

What conditions does trial NCT00673842 study?

This clinical trial studies the following conditions: Myocardial Infarction, Sudden Death. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00673842?

The interventions under investigation include: Usual care (OTHER), Implantable Cardioverter Defibrillator + Usual Care (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00673842?

This trial is sponsored by University of Calgary, which has 64 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00673842 being conducted?

This trial has 20 study locations across Alabama, Colorado, Florida, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial